Author: [No authors listed]
Conference/Journal: J Clin Oncol.
Date published: 2016 Jan 20
Other: Volume ID: 34 , Issue ID: 3_suppl , Pages: e292 , Special Notes: doi: 10.1200/jco.2016.34.3_suppl.e292. , Word Count: 320
e292 Background: This is a pilot study update on the potential of MET to up-regulate TP53AIP1 gene expression correlated with the up-regulation TP53 gene expression in patients diagnosed with breast cancer.
METHODS: The selection process for the study participants was nonrandom. The following was the eligibility criteria. 1.) Inclusion Criteria: Breast Cancer, Stages II, III. 2.) Exclusion Criteria: Cognitively impaired, weak or ill. The study utilized two groups. Each group was assigned two research participants. Group One received one session of MET. Group Two received two sessions of MET. Each MET session was approximately 25-35 minutes in duration. Blood samples were taken at baseline and post-MET sessions to provide evidence in gene expression changes. For Group Two, the post-MET session blood draw was done 7 days after baseline. 1.) Primary Endpoint: To determine whether MET can up-regulate TP53AIP1 gene expression. 2.) Secondary Endpoint:To determine whether there is a correlation between up-regulated TP53AIP1 gene expression and up-regulated TP53 gene expression. The blood samples were sent to genomics labs at the Childrens Hospital of Los Angeles and the University of Nevada Las Vegas for mRNA extraction and microarray analysis. The gene expression was measured by DNA microarray results using the "PrimeView gene chip" and "Partek Genomics Suite" statistical software.
RESULTS: For three participants, there was no statistical or biologically significant up-regulation in TP53AIP1 gene expression. However, one participant from Group 1 evidenced a biologically significant up-regulation of TP53AIP1 gene expression along with a biologically significant up-regulation of TP53 gene expression. One major limitation of these findings is the statistical insignificance of the results due to the small number of participants.
CONCLUSIONS: This pilot study evidenced the up-regulation of TP53AIP1 gene expression potentially due to MET and provided evidence supporting the established correlation between TP53 and TP53AIP1 gene expression that could induce apoptosis. This study also provided a foundation for a larger study with more participants.
PMID: 28151227 DOI: 10.1200/jco.2016.34.3_suppl.e292